

We fund the last stage to achieve full deployment of proven medical devices, technologies and therapies

Late-stage funding of deployed, proven, promising external medical devices, technologies and therapies that are already helping patients. Ensuring that the devices, technologies or therapies can be prescribed by a physician and reimbursed by insurance.

WHY WE INVEST

Many inventions, devices and therapies are backed early by investors who believe a particular effort will improve the world we live in. Some are not even in it for the money at that early stage. Grants and donations flow to founders in the early years. But after years of hard work, stress and sleepless nights developing in the dark, they run out of runway while standing inches from full deployment. At that stage, many founders feel completely abandoned, and many give up. All of that effort, for nothing.

We fill that gap.

We do it for the patient: less pain, better mobility, more happiness, and a rapid improvement in quality of life, made accessible through insurance coverage.

WHAT WE LOOK FOR

- Medical-grade biohacking with immediate, visible and measurable patient impact
- External medical devices, tools, and technology, not drugs or procedures
- FDA Class I and Class II medical devices
- Candidate for insurance reimbursement, not cash-pay
- Late-stage companies, equity investment of \$2M to \$10M

WHAT WE DO NOT INVEST IN

- No surgical procedures
- No invasive devices
- No implants
- No injectables
- No ingestibles
- No consumables
- No reactive or nuclear technology
- No prototypes

How we invest.

We invest for equity participation, and we invest in people. We do not lend for repayment with interest. We fund the CRO, the clinical sites and the device inventory for the post-market studies (Phase IV / PMCF) that earn a dedicated HCPCS or CPT reimbursement code and favorable payer coverage. In return, we take an equity-linked position, typically a convertible note or redeemable convertible preferred, and a board seat. We attend two board meetings before we invest. The technology and the numbers are critical, but a team's character is what we really invest in.

AREAS OF FOCUS

Conditions that affect quality of life, dignity, and autonomy: **pain, movement, eating, bathing, sleeping, anxiety, speech.** Anything that speeds recovery or shortens a hospital stay. External medical devices (instrument, apparatus, equipment, prosthesis, hardware, wearable, tracker, monitor, sensor, peripheral, and similar), never inside the body.

Neurological & mobility. Parkinson's, Multiple Sclerosis, Stroke, Shingles, partial paralysis, congenital malformation, essential tremor, spasticity, cognitive decline.

Head & nerve. Migraines, tinnitus, vertigo and balance disorders.

Comfort and tolerability during treatment. Radiation, immunotherapy, dialysis.

Joint & musculoskeletal, the common, everyday things. Bone spurs, rotator cuff, knee pain, ankle pain, carpal tunnel, tennis elbow, arthritis impeding dexterity, chronic low back pain and sciatica.

Autoimmune & metabolic. Lupus, lipedema, fluoroquinolone toxicity, diabetic peripheral neuropathy, lymphedema, sleep apnea, urinary incontinence.

SECONDARY AREA OF INTEREST

GSA contract, defense, diplomatic and technology applications; prisons and incarceration systems; and senior living. The same discipline applies: rigorous research, close assessment of the people behind the product, and a product that is already deployed.

WHAT HAS TO BE TRUE

Proven. Patented. FDA-cleared. Management that is knowledgeable, honest, visionary, dedicated, invested, and of solid character. A clean pre-money balance sheet. Executives who are humble and respectful. We root for the underdog, and the underdog wins.

We fund the crucial step that unlocks the whole outcome.

In medical devices, the last stage before insurance pays, so that physicians can prescribe it for the benefit of the patients. Please feel free to contact us below.